* Amylin Pharmaceuticals Inc., of San Diego, acquired exclusivepatent rights to a compound found in the venom of the Gila monsterlizard. The compound, exendin, has shown effects known to beimportant for improving glucose control.

* Bio-Technology General Corp., of Iselin, N.J., said its humangrowth hormone Bio-Tropin received marketing approval in Brazil.The product is marketed in 19 countries.

* Biogen Inc., of Cambridge, Mass., said a judge for the U.S. DistrictCourt of the District of Columbia dismissed a lawsuit filed by BerlexLaboratories Inc., of Wayne, N.J., that claimed the FDA should nothave approved the multiple sclerosis product Avonex (interferonbeta-1a). The drug has been on the market since May.

* Boehringer Mannheim GmbH, of Mannheim, Germany, will marketcertain enzymes for Recombinant BioCatalysis Inc., of Sharon Hill,Pa., on a worldwide, non-exclusive basis.

* COR Therapeutics Inc., of South San Francisco, amended itsagreement with Ortho Pharmaceutical Corp. to extend a collaborativeresearch deal with a subsidiary of Johnson & Johnson, of NewBrunswick, N.J. COR will receive a research fee of $2.4 million inDecember and J&J purchased 400,000 shares of COR stock for $4million.

* Dyax Corp., of Cambridge, Mass., signed new licensing agreementswith five companies to use its phage display technology intherapeutic and certain diagnostic and research applications. Thecompany now has 10 such license deals.

* PathoGenesis Corp., of Seattle, completed two double-blindplacebo-controlled Phase III trials of TOBI (tobramycin forinhalation) for treating chronic lung infections in cystic fibrosispatients. The company said it expects to release results in the firstquarter of 1997 and file a new drug application by the end of thesecond quarter.

* Pharmacopeia Inc., of Princeton, N.J., said it reached a cashmilestone in its collaboration with Schering-Plough Corp., ofMadison, N.J., which will begin work on a lead compound identifiedfrom a Pharmacopeia library. The collaboration, in the areas ofcancer and asthma, was extended for an additional year.

* The Immune Response Corp., of Carlsbad, Calif., agreed todevelop and distribute its AIDS vaccine Remune in South andCentral America with Viru-Tech Ltd.. Privately held Viru-Techpurchased $3 million of Immune Response stock at $12.77 per shareand will pay for any clinical trials.

* Vivus Inc., of Menlo Park, Calif., received an approvable letterfrom the FDA for the use of MUSE (alprostadil) in treatingimpotence.

(c) 1997 American Health Consultants. All rights reserved.

No Comments